samedan logo
 
 
 
spacer
home > ebr > summer 2003 > maximising return on investment with r&d portfolio management
PUBLICATIONS
European Biopharmaceutical Review

Maximising Return on Investment with R&D Portfolio Management

Product prioritisation at a tactical level - identifying the most desirable and attractive products in a company's R&D pipeline - remains the primary focus of portfolio management today. This factor, coupled with the need to maximise return on investment, acts as a strong driving force for pharmaceutical companies to perform portfolio management.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Morten Soegaard, Research Analyst at Frost & Sullivan


Morten Soegaard, a Research Analyst at Frost & Sullivan, has recently finished his analysis on R&D Portfolio Management. As a member of the pharmaceuticals team he previously investigated the European market on commercial opportunities for inhalation drug delivery in diabetes.

spacer
Morten Soegaard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Antibody Internalization: Advanced Flow Cytometry and Live-Cell Analysis Give Rich Insights During Antibody Profiling

Sartorius Group

The natural characteristics of antibodies, such as high binding affinity, specificity to a wide variety of targets, and good stability, make them ideal therapeutic candidates for many diseases. Monoclonal antibodies (mAbs), in particular, deliver promising therapeutic results in several different disease areas, such as autoimmunity, oncology, and chronic inflammation. Researchers’ abilities to improve the breadth of antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody design techniques create the need for new screening methods so that lead candidates can be quickly and effectively identified as early in the development process as possible.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement